DNLI
Price
$20.47
Change
+$0.75 (+3.80%)
Updated
Sep 21 closing price
Capitalization
3.15B
50 days until earnings call
Intraday BUY SELL Signals
TNXP
Price
$10.72
Change
-$0.15 (-1.38%)
Updated
Sep 21 closing price
Capitalization
186.43M
48 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DNLI vs TNXP

DNLI vs TNXP Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
DNLI vs. TNXP commentary
Sep 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and TNXP is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($3.15B) has a higher market cap than TNXP($186M). DNLI has higher P/E ratio than TNXP: DNLI (62.89) vs TNXP (0.05). DNLI YTD gains are higher at: 23.985 vs. TNXP (-31.370). TNXP has higher annual earnings (EBITDA): -162.89M vs. DNLI (-526.81M). DNLI has more cash in the bank: 710M vs. TNXP (176M). TNXP has less debt than DNLI: TNXP (1.27M) vs DNLI (32.2M). TNXP has higher revenues than DNLI: TNXP (29.1M) vs DNLI (3.6M).
DNLITNXPDNLI / TNXP
Capitalization3.15B186M1,695%
EBITDA-526.81M-162.89M323%
Gain YTD23.985-31.370-76%
P/E Ratio62.890.05117,358%
Revenue3.6M29.1M12%
Total Cash710M176M403%
Total Debt32.2M1.27M2,531%
FUNDAMENTALS RATINGS
DNLI vs TNXP: Fundamental Ratings
DNLI
TNXP
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
12
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
6281
P/E GROWTH RATING
1..100
9962
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TNXP's Valuation (12) in the Pharmaceuticals Other industry is significantly better than the same rating for DNLI (90) in the Biotechnology industry. This means that TNXP’s stock grew significantly faster than DNLI’s over the last 12 months.

TNXP's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as DNLI (100) in the Biotechnology industry. This means that TNXP’s stock grew similarly to DNLI’s over the last 12 months.

TNXP's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as DNLI (98) in the Biotechnology industry. This means that TNXP’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's Price Growth Rating (62) in the Biotechnology industry is in the same range as TNXP (81) in the Pharmaceuticals Other industry. This means that DNLI’s stock grew similarly to TNXP’s over the last 12 months.

TNXP's P/E Growth Rating (62) in the Pharmaceuticals Other industry is somewhat better than the same rating for DNLI (99) in the Biotechnology industry. This means that TNXP’s stock grew somewhat faster than DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLITNXP
RSI
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
77%
Momentum
ODDS (%)
Bearish Trend 4 days ago
82%
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bearish Trend 4 days ago
78%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
82%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 22 days ago
80%
Declines
ODDS (%)
Bearish Trend 6 days ago
80%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
82%
Aroon
ODDS (%)
Bearish Trend 4 days ago
81%
Bullish Trend 4 days ago
79%
COMPARISON
Comparison
Sep 22, 2026
Stock price -- (DNLI: $20.47 vs. TNXP: $10.72)
Brand notoriety: DNLI and TNXP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 193% vs. TNXP: 98%
Market capitalization -- DNLI: $3.15B vs. TNXP: $186.43M
DNLI [@Biotechnology] is valued at $3.15B. TNXP’s [@Biotechnology] market capitalization is $186.43M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $128.84B. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green while TNXP’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • TNXP’s FA Score: 1 green, 4 red.
According to our system of comparison, TNXP is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 3 TA indicator(s) are bullish while TNXP’s TA Score has 6 bullish TA indicator(s).

  • DNLI’s TA Score: 3 bullish, 6 bearish.
  • TNXP’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, TNXP is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а -3.53% price change this week, while TNXP (@Biotechnology) price change was -8.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.13%. For the same industry, the average monthly price growth was -8.15%, and the average quarterly price growth was +5.00%.

Reported Earning Dates

DNLI is expected to report earnings on Nov 11, 2026.

TNXP is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (-2.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
DNLI
Daily Signal:
Gain/Loss:
TNXP
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
WCBR45.401.94
+4.47%
WisdomTree Cybersecurity Fund (WCBR)
GGRW37.791.52
+4.18%
Gabelli Growth Innovators ETF (GGRW)
DCOR84.290.97
+1.17%
Dimensional US Core Equity 1 ETF (DCOR)
APRT47.100.21
+0.45%
AllianzIM U.S. Equity Buffer10 Apr ETF (APRT)
STOT46.500.01
+0.02%
State Street DoubleLine Short Duration Total Return Tactical ETF (STOT)